|
COMBI-MB: A phase II study of combination dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant (mut) melanoma brain metastases (MBM). |
|
|
Consulting or Advisory Role - Genentech/Roche; GlaxoSmithKline; Novartis; Sanofi; Vaccinex |
Research Funding - AstraZeneca (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Myriad Genetics (Inst); Oncothyreon (Inst); Sanofi (Inst) |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Merck Serono; Novartis; Roche |
|
|
Honoraria - Bristol-Myers Squibb; Merck; Roche |
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; MERCK; Novartis; Pierre Fabre; Roche/Genentech |
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Roche/Genentech |
|
|
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Roche |
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Roche |
Speakers' Bureau - Novartis |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Roche |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Roche |
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Roche |
Speakers' Bureau - Bristol-Myers Squibb; MSD; Novartis; Roche |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche |
|
|
Speakers' Bureau - Bristol-Myers Squibb; Merck Serono; MSD Oncology; Novartis; Roche |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Roche |
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Roche |
Speakers' Bureau - MSD; Novartis; Roche |
Research Funding - Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Roche |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Novartis; Novartis (Inst); Roche; Roche (Inst) |
Research Funding - Bristol-Myers Squibb (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Roche |
|
|
Consulting or Advisory Role - Amgen; Castle Biosciences; Merck Sharp & Dohme; Prometheus |
Research Funding - Amgen; Genentech/Roche; Merck Sharp & Dohme; Pharmacyclics |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; EMD Serono; Merck; Novartis; Roche |
Expert Testimony - EMD Serono |
|
|
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Roche |
Consulting or Advisory Role - Amgen; Bioncotech; Bristol-Myers Squibb; MSD; Novartis; Roche |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD |
|
|
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Roche |
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Roche |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Novartis; Roche |
Research Funding - Bristol-Myers Squibb (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Roche |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche |
Research Funding - Bristol-Myers Squibb |
Expert Testimony - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche |
|
|
|
|
|
|
Stock and Other Ownership Interests - Bristol-Myers Squibb; GlaxoSmithKline; Novartis |
|
|
Employment - GlaxoSmithKline; Novartis |
Stock and Other Ownership Interests - AstraZeneca; GlaxoSmithKline; Incyte; Novartis |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche |
Research Funding - Bristol-Myers Squibb; Novartis; Roche |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Roche |